Gut Stress Hormone GDF15 Emerges as a Double-Edged Target in Inflammatory Bowel Disease
GDF15 is elevated in Crohn's and ulcerative colitis and may loosen the gut barrier, but small studies leave its true role unclear.

Summary
Growth differentiation factor 15 (GDF15) is a stress-responsive protein that rises in many chronic diseases. This commentary reviews six observational studies and a recent mechanistic report in inflammatory bowel disease (IBD). Most studies found higher circulating GDF15 in Crohn's disease and ulcerative colitis than in controls, and levels tracked inflammatory markers like IL-6 and CRP. In lab models using colonic organoids and T84 cells, GDF15 reduced the tight-junction proteins ZO-1 and claudin 1 and increased gut permeability. Yet animal work suggests GDF15 can also protect the mucosa. The authors conclude GDF15 is a double-edged mediator. Small cohorts, mostly patients in remission, and a lack of genetic validation mean it is too early to use GDF15 as a clinical biomarker or drug target.
Detailed Summary
Inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, is a chronic, relapsing condition driven by genetics, immune dysregulation, gut microbes, and environment. Better biomarkers and new targets are needed. Growth differentiation factor 15 (GDF15), a TGF-β superfamily member that rises with cellular stress, kidney and heart failure, liver disease, cancer cachexia, and mitochondrial disease, has become a candidate. This commentary evaluates a study by Ruiz-Malagón and colleagues and places it in the wider literature.
The authors reviewed six observational studies of circulating GDF15 in IBD. Four (Tonkic, Koureta, Kučerka, Ruiz-Malagón) found higher levels in both Crohn's and ulcerative colitis than in controls, while Ramasamy found no clear difference in ulcerative colitis. Higher GDF15 was seen in Crohn's patients with low skeletal muscle index. It correlated with age and IL-6 in one study, with Crohn's flares and with IL-6 in ulcerative colitis in another. Levels were higher in patients on azathioprine without biologics. Fecal calprotectin has not shown a clear link to GDF15, possibly because cohorts were small and mostly in remission or mild disease.
The focal study measured plasma GDF15 in 21 Crohn's patients, 18 ulcerative colitis patients, and 23 healthy controls, finding elevated levels that correlated with inflammatory and permeability markers. In colonic organoids and T84 epithelial cells, GDF15 increased permeability by lowering ZO-1 and claudin 1, key tight-junction proteins. This suggests a pathogenic role and raises the possibility that inhibiting GDF15 could help preserve the gut barrier.
The picture is complicated. GDF15 was first described as a macrophage-inhibiting cytokine and may promote anti-inflammatory M2-like polarization, and it protects in some acute inflammation and sepsis models. A mouse study found GDF15 deficiency worsened DSS colitis, impaired mucus production, and shifted mucin-degrading bacteria such as Akkermansia muciniphila. Its receptor GFRAL, with RET as co-receptor, was thought restricted to the brainstem, where it drives appetite suppression and weight loss. Low levels have now been detected in the mouse small intestine, but which receptors and cells mediate gut effects is unknown.
The authors stress caution. It remains unclear whether GDF15 is a bystander marker or a causal driver, and whether it outperforms existing markers for predicting flares or treatment response. Genetic validation (knockout or overexpression), larger independent cohorts, stratification by disease activity, age, and smoking, and eventually randomized trials are needed. Cost-effectiveness of any GDF15-targeted therapy cannot yet be assessed.
Key Findings
- Most observational studies found higher circulating GDF15 in Crohn's and ulcerative colitis than in healthy controls; one found no ulcerative colitis difference.
- GDF15 levels tracked IL-6 and CRP in some cohorts, and were higher in Crohn's patients with low skeletal muscle index.
- In colonic organoids and T84 cells, GDF15 raised permeability by reducing tight-junction proteins ZO-1 and claudin 1.
- GDF15-deficient mice had worse DSS colitis, less mucus and altered mucin-degrading bacteria, suggesting GDF15 can also be protective.
- GFRAL, once thought brainstem-only, is faintly detectable in mouse intestine, but the gut receptor and signaling pathway remain unknown.
Methodology
This is an invited commentary reviewing six observational human studies of circulating GDF15 in IBD and a focal paper by Ruiz-Malagón et al. combining plasma measurements (21 Crohn's, 18 ulcerative colitis, 23 controls) with colonic organoid and T84 cell experiments. It draws on supporting mouse and receptor-biology literature but contains no new data.
Study Limitations
Cohorts are small and mostly in remission or mild disease, causal direction is unresolved, and the barrier findings rest on in vitro models without genetic validation. GDF15 shows both protective and pathogenic effects depending on context, and no trial data exist for GDF15-targeted therapy.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
